ロシュ・ホールディングは、乳がん薬ギレデストラントの第3相persevERA試験が主要評価項目を達成できなかったことを受け、株価が大幅に下落した。この挫折にもかかわらず、同社は同薬の他の適応症での可能性に楽観的であり続けている。アナリストらは、この結果をロシュの広範なポートフォリオにとって存在を脅かすものではない障害と見なしている。
ロシュ・ホールディング（ティッカーRHHBYおよびRHHBF）は、2026年3月11日、第3相persevERA試験の失望的な結果を発表した後、株価が顕著に下落した。この試験は実験的な乳がん治療薬ギレデストラントを検証したが、主要評価項目を達成しなかった。
AIによるレポート AIによって生成された画像 事実確認済み
New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.
Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.
AIによるレポート
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
French-owned energy firm Engie announced its withdrawal from the Chilean Association of Renewables and Storage (Acera). It stated that the association's current makeup does not align with its comprehensive utility vision for the energy transition. This marks the second major exit from the group in recent times.
AIによるレポート
Hims & Hers Health posted a revenue miss in the first quarter amid margin pressures.
Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.
AIによるレポート
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.